A Note on Safety We built medicinal-use.com to help make sense of the UK’s changing laws, but we aren’t doctors. This content is for research and education—it isn’t medical advice. Before changing your healthcare routine or starting a new treatment, please speak with a GMC-registered clinician. Your safety matters more than any article we write.
[my_disclaimer]
Migraine and cluster headaches affect millions in the UK, with migraine alone impacting ~1 in 7 adults. Standard treatments (triptans, preventives like beta-blockers/topiramate, CGRP inhibitors) help many, but some patients experience limited relief, side effects, or chronic refractory cases. In 2025, private specialist clinics prescribe CBPMs for migraine and cluster headache symptoms when other options have failed, with growing real-world evidence from UK registries showing benefits for some patients.
This guide covers current evidence, access, product considerations, and risks.
1. Evidence for CBPMs in Migraine & Cluster Headaches (2025 Update)
Evidence is promising but mostly observational — limited large RCTs exist.
- Real-World UK Data UK Medical Cannabis Registry and private clinic outcomes show reductions in migraine frequency, severity, and associated symptoms (nausea, light sensitivity) at 1–6 months. Cluster headache patients report decreased attack frequency and intensity. Headache disorders are among top indications in private practice.
- CBD-Focused Evidence CBD shows potential anti-inflammatory and analgesic effects in preclinical models and small human studies, possibly reducing migraine triggers and pain.
- THC and Balanced Products THC may help acute pain and nausea; balanced THC/CBD products are commonly prescribed for preventive and acute use in private clinics.
- NHS Position NICE and NHS England do not recommend CBPMs for migraine or cluster headaches due to insufficient high-quality evidence. NHS access is extremely rare.
- Limitations Most data is from patient registries and case series. Long-term safety, optimal dosing, and THC/CBD ratios need more research. Some patients report no benefit or side effects.
2. Access for Migraine & Cluster Headaches in 2025
NHS — Virtually impossible (not NICE-approved).
Private Clinics — Realistic path for eligible patients. Eligibility: Chronic/refractory migraine or cluster headaches, 2+ conventional treatments tried (e.g., triptans, preventives) with insufficient benefit/side effects, medical records.
Process (Private)
- Self-refer to CQC-regulated clinic (e.g., Releaf, Alternaleaf, Curaleaf Clinic, Mamedica, Lyphe).
- Online eligibility check/upload records.
- Specialist consultation (£50–£200).
- Prescription if suitable (often balanced THC/CBD oils/capsules for prevention, or THC-dominant for acute attacks).
- Medication from licensed pharmacy (home delivery).
- Follow-ups (1–3 months).
Costs
- Consultation: £50–£200
- Medication: £50–£350+/month (balanced products often £150–£300)
- Follow-ups: £65–£150
3. CBD vs THC for Migraine & Cluster Headaches
| Aspect | CBD-Dominant Products | THC-Inclusive Products |
|---|---|---|
| Effects | May reduce inflammation, pain triggers, nausea | Acute pain relief, anti-nausea; may help cluster attacks |
| Common Forms | Oils, capsules, broad-spectrum (0% THC) | Balanced THC/CBD oils, capsules, flower |
| Evidence | Preliminary positive for prevention | Real-world reports for acute relief |
| Risks | Lower (fatigue rare) | Higher (dizziness, dependence, rebound headaches) |
| UK Private Use | Often first-line for prevention | Used for acute attacks when needed |
Clinics often start with CBD-dominant for prevention, adding THC for acute relief.
4. Risks and Side Effects
- Common: Dry mouth, fatigue, dizziness, appetite changes
- THC-related: Rebound headaches, dependence, cognitive effects, driving risks (DVLA strict)
- General: Interactions with triptans/preventives, worsening headaches in some
- Long-term: Limited data; potential for tolerance or medication-overuse headache
Specialists monitor closely.
5. Legal & Practical Notes
- CBPMs are prescription-only (Schedule 2).
- Possession without prescription illegal (Class B).
- Driving: Impairment windows apply — check DVLA.
- No NHS funding for migraine/cluster — full private cost.
Sources
- UK Medical Cannabis Registry patient outcomes
- NICE guidelines on CBPMs
- GMC specialist prescribing rules
- Real-world studies on cannabinoids and headache disorders (2023–2025)
- Clinic data (Releaf, Alternaleaf, Curaleaf)